fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Timolol maleate & travoprost

Form:

4 of 4 products shown

3 Limited Use · 1 not a benefit

Apo-Travoprost-Timop · DIN 02415305 · 0.5% & 0.004% · Oph Sol

Limited Use, Reason for Use code 310, 393 required; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health CanadaMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 310, 393 required; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below); DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Travoprost-Timop · DIN 02415305 Manufacturer: Apotex Inc.; listing date 2019-04-30 Health Canada: Marketed since 2020-03-03 · brand APO-TRAVOPROST-TIMOP PQ · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TRAVOPROST 0.004 %/W/V, TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Travoprost-Timop: Formulary list price $8.84 per unit (the source does not state the unit; exact figure $8.8425). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02415305)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02415305). DIN 02415305: Apo-Travoprost-Timop Raw flags: dinStatus=E, sec12=Y, sec3=Y Item: 523600116; group id 642; item number 1618; lccId 00198; manufacturer id APX Source form: Oph Sol; strength: 0.5% & 0.004% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; DIN status E, meaning unconfirmed Source prices (unrounded): $8.8425; ministry $8.8425 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02415305 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89992
Interchangeable products
DuoTrav · DIN 02278251 · not recorded
Shortage status: shortage reported ended August 28, 2026 (report last updated August 28, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02415305
Shortage record checked October 6, 2026

DuoTrav · DIN 02278251 · 0.5% & 0.004% · Oph Sol

Listed, not a benefitMarketed · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
DuoTrav · DIN 02278251 Manufacturer: Alcon Canada Inc.; listing date 2009-01-30 Health Canada: Marketed since 2018-01-19 · brand DUOTRAV PQ · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V, TRAVOPROST 0.004 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

DuoTrav: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02278251)

Source record
DIN 02278251: DuoTrav Raw flags: notABenefit=Y, sec3=Y Item: 523600116; group id 642; item number 1618; lccId 00198; manufacturer id ALC Source form: Oph Sol; strength: 0.5% & 0.004% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02278251 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76384
Interchangeable products
Apo-Travoprost-Timop · DIN 02415305 · $8.8425
Shortage status: active shortage (reported July 2, 2026, estimated to end October 19, 2026, last updated July 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02278251
Shortage record checked October 6, 2026

Apo-Travoprost-Timop PQ · PIN 09857644 · 0.5% & 0.004% · Oph Sol-5mL Pk

Limited Use, Reason for Use code 310, 393 requiredOntario PIN; no Health Canada record under this code
StatusLimited Use, Reason for Use code 310, 393 required
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02415305 (Marketed, 2020-03-03) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89992

Check Health Canada brand DIN
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Travoprost-Timop PQ · DIN 09857644 Manufacturer: Apotex Inc.; listing date 2020-06-30 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02415305 (Marketed, 2020-03-03) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89992
Re-check Health Canada status and shortages (live)

Apo-Travoprost-Timop PQ: Formulary list price $44.21 per unit (the source does not state the unit; exact figure $44.2125). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857644)

Source record
DIN 09857644: Apo-Travoprost-Timop PQ Raw flags: sec12=Y, sec3=Y Item: 523600139; group id 642; item number 1619; lccId 00198; manufacturer id APX Source form: Oph Sol-5mL Pk; strength: 0.5% & 0.004% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $44.2125; ministry $44.2125 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857644 Health Canada record for this brand: DIN 02415305 (Marketed, March 3, 2020) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89992 Therapeutic Notes (formulary) This product is stable for 120 days after opening. Please refer to the product monograph for more information.
Interchangeable products
DuoTrav PQ · DIN 09857513 · $44.2125
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857644
Shortage record checked October 6, 2026

DuoTrav PQ · PIN 09857513 · 0.5% & 0.004% · Oph Sol-5mL Pk

Limited Use, Reason for Use code 310, 393 requiredOntario PIN; no Health Canada record under this code
StatusLimited Use, Reason for Use code 310, 393 required
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02278251 (Marketed, 2018-01-19) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76384

Check Health Canada brand DIN
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Duotrav PQ (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
DuoTrav PQ · DIN 09857513 Manufacturer: Novartis Pharma Canada Inc.; listing date 2014-11-27 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02278251 (Marketed, 2018-01-19) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76384
Re-check Health Canada status and shortages (live)

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857513)

Source record
DIN 09857513: DuoTrav PQ Raw flags: sec12=Y, sec3=Y Item: 523600139; group id 642; item number 1619; lccId 00198; manufacturer id NOV Source form: Oph Sol-5mL Pk; strength: 0.5% & 0.004% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $56.7000; ministry $44.2125 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857513 Health Canada record for this brand: DIN 02278251 (Marketed, January 19, 2018) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76384 Therapeutic Notes (formulary) This product is stable for 120 days after opening. Please refer to the product monograph for more information.
Interchangeable products
Apo-Travoprost-Timop PQ · DIN 09857644 · $44.2125
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857513
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01ED): coverage varies; not interchangeable

  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Timolol (Timoptic-XE): general benefit, not a benefit
  • Brimonidine + timolol (Apo-Brimonidine-Timop): limited Use 310, 393
  • Brinzolamide + timolol (Azarga): limited Use 310, 393
  • Dorzolamide + timolol (Cosopt): limited Use 310, 393

11 more in the class list below

Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk

LATANOPROST & TIMOLOL MALEATE

· 9 products · Limited Use, codes 310, 393 · strengths: 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS DUOTRAV® PQ (travoprost and timolol) is indicated for the reduction of elevated IOP in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins, or other IOP lowering agents AND when the use of DUOTRAV PQ (the fixed combination drug) is considered appropriate. DUOTRAV PQ should not be used to initiate therapy. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatics (>65 years of age): No overall differences in safety or effectiveness have been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00059283.PDF PM date: December 17, 2020 Source product: DUOTRAV PQ; DIN 02278251; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Travoprost-Timop · DIN 02415305 Shortage status: shortage reported ended 2026-08-28 (report last updated 2026-08-28); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02415305

Check this DIN again

DuoTrav · DIN 02278251 Shortage status: active shortage (reported 2026-07-02, estimated to end 2026-10-19, last updated 2026-07-20); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02278251

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For DuoTrav: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026